Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

Read more breaking news


News in brief

PPD shareholders support private equity takeover


PPD shareholders have cleared the way for private equity firms to buy the CRO by voting in favour of the takeover.

At a meeting 96.4 per cent of attending PPD shareholders voted in favour of the $3.9bn (€2.9bn) takeover. The deal is still subject to certain closing conditions but once these are cleared each stockholder will receive $33.25 a share.


For PPD executives this amounts to a big payday. Shareholders voted in favour of ‘golden parachute’ payments totalling more than $20m. PPD founder Fred Eshelman will receive $6.7m and incoming CEO Raymond Hill, who took the job in September, is in line for a $3.1m payment.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...